EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost‐Effectiveness Analysis

Wanyi Chen, Paula M Luz iD, Anjali Srinivasan, Beatriz Grinsztejn, Justine A Scott, Anne M Neilan, Valdiléa G Veloso, Caitlin M Dugdale, Kenneth A Freedberg

Journal of the International AIDS Society · 2026-05 · 29 (5)

DOI: 10.1002/jia2.70116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, online erschienen am 14.05.2026. Verfasst von Wanyi Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In Brazil, men who have sex with men (MSM) and transgender women (TGW) remain heavily affected by HIV. Long‐acting pre‐exposure prophylaxis (LA PrEP) with injectable cabotegravir (CAB‐LA) or lenacapavir (LEN‐LA) is more effective at preventing HIV acquisition than oral PrEP. Our objective was to assess the potential clinical and economic impact of offering CAB‐LA or LEN‐LA to MSM and TGW with high vulnerability to HIV acquisition in Brazil and determine the maximum cost at which they would be cost‐effective.

Methods

We used the CEPAC microsimulation model of HIV prevention and treatment to evaluate two strategies for MSM and TGW aged 18−49: (1) SOC : standard‐of‐care oral PrEP at current coverage, and (2) SOC+LA : offering oral and LA PrEP (either CAB‐LA or LEN‐LA). Input parameters are derived from Brazil‐based data from 2010 to 2024 and published studies: HIV incidence (%/year, MSM: 3.4 [age 18−29 years], 1.1 [30−49 years]; TGW: 5.0 [18−29 years], 1.7 [30−49 years]), relative risk reduction, LA versus oral PrEP (66% [CAB‐LA]; 89% [LEN‐LA]), PrEP coverage (20% [oral PrEP]; 20% [LA PrEP]) and oral PrEP cost (programmatic+drug = $207/year). Outcomes include lifetime HIV risk, life expectancy (LE) and incremental cost‐effectiveness ratio (ICER) of SOC+LA versus SOC in 2024 USD/year of life saved (YLS). We identified the maximum LA PrEP cost with ICER below the established Brazilian willingness‐to‐pay threshold of $8740/YLS.

Results

Compared to SOC, SOC+CAB‐LA would decrease MSM lifetime HIV risk from 21.4% to 16.8%, increase undiscounted LE from 39.0 to 39.4 years. For TGW, SOC+CAB‐ LA would decrease lifetime HIV risk from 29.5% to 23.4%, increase LE from 36.0 to 36.9 years. Results for SOC+LEN‐LA would be similar to SOC+CAB‐LA . SOC+LA would remain cost‐effective for MSM at cost below $710/year for CAB‐LA and $740/year for LEN‐LA. Findings are most sensitive to LA PrEP cost, HIV incidence, and whether and by how much LA PrEP increases coverage.

Conclusions

Offering LA PrEP with cabotegravir or lenacapavir in addition to oral PrEP for MSM and TGW in Brazil could markedly improve clinical outcomes and be cost‐effective at ∼$700/year. Cost agreements are critical to ensure these prevention options are accessible in high‐incidence settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisAnti-HIV AgentsHumansCost-Benefit AnalysisCost-Effectiveness AnalysisBrazilMaleAdultAdolescentFemaleYoung AdultMiddle AgedHomosexuality, MaleTransgender Persons

Stichwörter der Autor:innen

BrazilHIVMSMTGWcost‐effectiveness analysislong‐acting PrEP

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, de Janeiro, Brazil.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Center for AIDS Research, Harvard University, Cambridge, Massachusetts, USA.
  • Division of General Academic Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Paula M Luz

Förderung

  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NICHD NIH HHS

Zitieren

APA

Chen, W., Luz, P. M., Srinivasan, A., Grinsztejn, B., Scott, J. A., Neilan, A. M., Veloso, V. G., Dugdale, C. M., & Freedberg, K. A. (2026). Long‐Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost‐Effectiveness Analysis. Journal of the International AIDS Society, 29(5). https://doi.org/10.1002/jia2.70116

Vancouver

Chen W, Luz PM, Srinivasan A, Grinsztejn B, Scott JA, Neilan AM, et al. Long‐Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost‐Effectiveness Analysis. Journal of the International AIDS Society. 2026;29(5). doi:10.1002/jia2.70116

BibTeX
@article{Chen2026,
  author = {Chen, Wanyi and Luz, Paula M and Srinivasan, Anjali and Grinsztejn, Beatriz and Scott, Justine A and Neilan, Anne M and Veloso, Valdiléa G and Dugdale, Caitlin M and Freedberg, Kenneth A},
  title = {Long‐Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost‐Effectiveness Analysis},
  journal = {Journal of the International AIDS Society},
  year = {2026},
  volume = {29},
  number = {5},
  doi = {10.1002/jia2.70116}
}
Kostenlos starten →